PDE10A Activators
PDE10A Activators, through a range of indirect mechanisms, significantly enhance the activity of PDE10A, an enzyme critical for the hydrolysis of cyclic nucleotides cAMP and cGMP, playing a vital role in neuronal signaling and various other physiological processes. Non-selective phosphodiesterase inhibitors like Papaverine, IBMX, Caffeine, and Theophylline increase the levels of both cAMP and cGMP, thereby indirectly influencing PDE10A's regulatory function. This elevation in cyclic nucleotide levels shifts the balance of activity towards PDE10A, enabling it to play a more prominent role in the modulation of these crucial signaling molecules. Such alterations in cyclic nucleotide levels are essential for the fine-tuning of various physiological responses, including neuronal signaling pathways where PDE10A is a key modulator.
In addition to these broad-spectrum inhibitors, selective PDE inhibitors like Rolipram, Zaprinast (M&B 22948), Vinpocetine, Milrinone, Sildenafil, Tadalafil, and Vardenafil, Hydrochloride Salt also contribute to the modulation of PDE10A activity. By specifically targeting other PDEs like PDE4, PDE5, and PDE1, these compounds indirectly cause an accumulation of cAMP or cGMP, which then indirectly impacts PDE10A's function. The increased cGMP levels due to PDE5 inhibitors like Sildenafil, Tadalafil, and Vardenafil, Hydrochloride Salt are particularly significant in neuronal and cardiovascular tissues where PDE10A plays a crucial role. This accumulation of cyclic nucleotides indirectly facilitates the hydrolytic activity of PDE10A, emphasizing its importance in the regulation of intracellular signaling pathways. The collective action of these activators underscores the intricate regulation of PDE10A, highlighting its essential role in maintaining the balance of cellular responses mediated by cAMP and cGMP.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine, a non-selective phosphodiesterase inhibitor, indirectly enhances PDE10A activity by inhibiting other PDEs. This leads to an altered balance of cyclic nucleotides, indirectly impacting PDE10A's role in modulating cAMP and cGMP levels. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a non-selective PDE inhibitor, indirectly enhances PDE10A activity by inhibiting various PDEs and altering levels of cAMP and cGMP. This change in cyclic nucleotide levels indirectly influences PDE10A's regulatory role in neuronal signaling. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine, a non-selective PDE inhibitor, indirectly enhances PDE10A activity by increasing intracellular cAMP and cGMP levels. This elevation indirectly affects PDE10A's function in hydrolyzing these nucleotides. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective PDE4 inhibitor, indirectly influences PDE10A activity by increasing cAMP levels. Elevated cAMP indirectly impacts PDE10A's role in cAMP and cGMP hydrolysis, relevant to neuronal pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast (M&B 22948), primarily a PDE5 inhibitor, indirectly enhances PDE10A activity by increasing cGMP levels. This modulation of cGMP levels can indirectly influence PDE10A's role in cyclic nucleotide signaling in neurons. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective PDE inhibitor, indirectly impacts PDE10A activity by elevating cAMP and cGMP levels. This elevation can indirectly affect PDE10A's function in modulating these nucleotides in various tissues. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine, a PDE1 inhibitor, indirectly enhances PDE10A activity by altering cAMP and cGMP levels. This change can indirectly influence PDE10A's role in hydrolyzing these nucleotides, particularly in the brain. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, indirectly impacts PDE10A activity by increasing cAMP levels, thereby indirectly influencing PDE10A's role in cyclic nucleotide signaling and hydrolysis. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole, a non-selective PDE inhibitor, indirectly influences PDE10A activity by increasing cAMP and cGMP levels, thereby indirectly affecting PDE10A's function in hydrolyzing these nucleotides. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil, predominantly a PDE5 inhibitor, indirectly enhances PDE10A activity by elevating cGMP levels. This elevation indirectly influences PDE10A's function in cyclic nucleotide signaling, particularly in the brain and vascular tissues. | ||||||